Astragaloside IV
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 600143

CAS#: 84687-43-4

Description: Astragaloside IV (AS-IV), the major active component extracted from Astragalus membranaceus, has broad application prospects, especially in cardiovascular diseases, digestive diseases, cancer and other modern high incidence, high-risk diseases, and could be developed as a medicine. Protective effects of Astrageloside IV include the cardiovascular system, immune, digestive, nervous system were identified, and the action mechanisms were associated with regulation of the calcium balance, anti-oxydant, antiapoptosis, antivirus, and so on.


Chemical Structure

img
Astragaloside IV
CAS# 84687-43-4

Theoretical Analysis

MedKoo Cat#: 600143
Name: Astragaloside IV
CAS#: 84687-43-4
Chemical Formula: C41H68O14
Exact Mass: 784.46091
Molecular Weight: 784.97
Elemental Analysis: C, 62.73; H, 8.73; O, 28.54

Price and Availability

Size Price Availability Quantity
5.0mg USD 220.0 2 Weeks
10.0mg USD 400.0 2 Weeks
Bulk inquiry

Synonym: Astragaloside IV

IUPAC/Chemical Name: (2R,3R,4S,5S,6R)-2-(((2aR,3R,4R,5aS,7R,11aR)-4-hydroxy-3-((2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-2a,5a,8,8-tetramethyl-9-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)hexadecahydrocyclopenta[a]cyclopropa[e]phenanthren-7-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.

InChi Key: QMNWISYXSJWHRY-CSXKERSZSA-N

InChi Code: InChI=1S/C41H68O14/c1-35(2)24(54-33-29(48)26(45)20(44)17-51-33)9-11-41-18-40(41)13-12-37(5)31(39(7)10-8-25(55-39)36(3,4)50)19(43)15-38(37,6)23(40)14-21(32(35)41)52-34-30(49)28(47)27(46)22(16-42)53-34/h19-34,42-50H,8-18H2,1-7H3/t19-,20-,21-,22-,23?,24?,25+,26+,27-,28+,29-,30-,31+,32?,33+,34-,37-,38+,39-,40?,41-/m1/s1

SMILES Code: C[C@]12CCC34C[C@@]35CCC(O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)C(C)(C)C5[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)CC4[C@]1(C)C[C@@H](O)[C@@H]2[C@@]8(C)CC[C@@H](C(C)(O)C)O8

Appearance: solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 784.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Cheng X, Gu J, Zhang M, Yuan J, Zhao B, Jiang J, Jia X. Astragaloside IV inhibits migration and invasion in human lung cancer A549 cells via regulating PKC-α-ERK1/2-NF-κB pathway. Int Immunopharmacol. 2014 Sep 10. pii: S1567-5769(14)00341-5. doi: 10.1016/j.intimp.2014.08.027. [Epub ahead of print] PubMed PMID: 25218161.

2: Zhang X, Chen J. The mechanism of astragaloside IV promoting sciatic nerve regeneration. Neural Regen Res. 2013 Aug 25;8(24):2256-65. doi: 10.3969/j.issn.1673-5374.2013.24.005. PubMed PMID: 25206535; PubMed Central PMCID: PMC4146037.

3: Chen Z, Cai Y, Zhang W, Liu X, Liu S. Astragaloside IV inhibits platelet-derived growth factor-BB-stimulated proliferation and migration of vascular smooth muscle cells via the inhibition of p38 MAPK signaling. Exp Ther Med. 2014 Oct;8(4):1253-1258. Epub 2014 Aug 14. PubMed PMID: 25187834; PubMed Central PMCID: PMC4151649.

4: Qiu YY, Zhu JX, Bian T, Gao F, Qian XF, Du Q, Yuan MY, Sun H, Shi LZ, Yu MH. Protective Effects of Astragaloside IV against Ovalbumin-Induced Lung Inflammation Are Regulated/Mediated by T-bet/GATA-3. Pharmacology. 2014 Aug 28;94(1-2):51-59. [Epub ahead of print] PubMed PMID: 25171656.

5: Shao A, Guo S, Tu S, Ammar AB, Tang J, Hong Y, Wu H, Zhang J. Astragaloside IV alleviates early brain injury following experimental subarachnoid hemorrhage in rats. Int J Med Sci. 2014 Aug 8;11(10):1073-81. doi: 10.7150/ijms.9282. eCollection 2014. PubMed PMID: 25136262; PubMed Central PMCID: PMC4135229.

6: Chen Y, Gui D, Chen J, He D, Luo Y, Wang N. Down-regulation of PERK-ATF4-CHOP pathway by Astragaloside IV is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats. Cell Physiol Biochem. 2014;33(6):1975-87. PubMed PMID: 25012492.

7: Liu QS, Wang HF, Sun AK, Huo XP, Liu JL, Ma SH, Peng N, Hu J. A comparative study on inhibition of total astragalus saponins and astragaloside IV on TNFR1-mediated signaling pathways in arterial endothelial cells. PLoS One. 2014 Jul 3;9(7):e101504. doi: 10.1371/journal.pone.0101504. eCollection 2014. PubMed PMID: 24991819; PubMed Central PMCID: PMC4081628.

8: Zhang A, Zheng Y, Que Z, Zhang L, Lin S, Le V, Liu J, Tian J. Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO. J Cancer Res Clin Oncol. 2014 Jul 1. [Epub ahead of print] PubMed PMID: 24980548.

9: Xu W, Shao X, Tian L, Gu L, Zhang M, Wang Q, Wu B, Wang L, Yao J, Xu X, Mou S, Ni Z. Astragaloside IV ameliorates renal fibrosis via the inhibition of mitogen-activated protein kinases and antiapoptosis in vivo and in vitro. J Pharmacol Exp Ther. 2014 Sep;350(3):552-62. doi: 10.1124/jpet.114.214205. Epub 2014 Jun 20. PubMed PMID: 24951279.

10: Sun Q, Jia N, Wang W, Jin H, Xu J, Hu H. Protective effects of astragaloside IV against amyloid beta1-42 neurotoxicity by inhibiting the mitochondrial permeability transition pore opening. PLoS One. 2014 Jun 6;9(6):e98866. doi: 10.1371/journal.pone.0098866. eCollection 2014. PubMed PMID: 24905226; PubMed Central PMCID: PMC4048237.